A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. by Smith, Catherine C et al.
Providence St. Joseph Health 
Providence St. Joseph Health Digital Commons 
Articles, Abstracts, and Reports 
4-28-2020 
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in 
relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. 
Catherine C Smith 
Mark J Levis 
Olga Frankfurt 
John M Pagel 
SWEDISH CANCER INSTITUTE. 
Gail J Roboz 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications 
 Part of the Hematology Commons, and the Oncology Commons 
Recommended Citation 
Smith, Catherine C; Levis, Mark J; Frankfurt, Olga; Pagel, John M; Roboz, Gail J; Stone, Richard M; Wang, 
Eunice S; Severson, Paul L; West, Brian L; Le, Mai H; Kayser, Sabine; Lam, Bao; Hsu, Henry H; Zhang, Chao; 
Bollag, Gideon; and Perl, Alexander E, "A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in 
relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia." (2020). Articles, Abstracts, and Reports. 
3035. 
https://digitalcommons.psjhealth.org/publications/3035 
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has 
been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. 
Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org. 
Authors 
Catherine C Smith, Mark J Levis, Olga Frankfurt, John M Pagel, Gail J Roboz, Richard M Stone, Eunice S 
Wang, Paul L Severson, Brian L West, Mai H Le, Sabine Kayser, Bao Lam, Henry H Hsu, Chao Zhang, 
Gideon Bollag, and Alexander E Perl 
This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/
publications/3035 
REGULAR ARTICLE
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Key Points
• Pexidartinib is safe and
well tolerated in re-
lapsed/refractory AML
patients.
• Pexidartinib, a type 2
inhibitor of FLT3, in-
cluding F691 gate-
keeper mutations, has
clinical activity in
FLT3-ITD–mutant AML
patients.
FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute
myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations,
but efficacy is limited by resistance-conferring kinase domain mutations. This phase 1/2
study evaluated the safety, tolerability, and efficacy of the oral FLT3 inhibitor PLX3397
(pexidartinib), which has activity against the FLT3 TKI–resistant F691L gatekeeper mutation
in relapsed/refractory FLT3-ITD–mutant AML. Ninety patients were treated: 34 in dose
escalation (part 1) and 56 in dose expansion (part 2). Doses of 800 to 5000 mg per day in
divided doses were tested. No maximally tolerated dose was reached. Plasma inhibitory
assay demonstrated that patients dosed with$3000mg had sufficient levels of active drug in
their trough plasma samples to achieve 95% inhibition of FLT3 phosphorylation in an FLT3-
ITD AML cell line. Based on a plateau in drug exposure, the 3000-mg dose was chosen as the
recommended phase 2 dose. The most frequently reported treatment-emergent adverse
events were diarrhea (50%), fatigue (47%), and nausea (46%). Based on modified response
criteria, the overall response rate to pexidartinib among all patients was 21%. Twenty-three
percent of patients treated at $2000 mg responded. The overall composite complete
response rate for the study was 11%. Six patients were successfully bridged to
transplantation. Median overall survival (OS) of patients treated in dose expansion was
112 days (90% confidence interval [CI], 77-150 days), and median OS of responders with
complete remission with or without recovery of blood counts was 265 days (90% CI, 170-422
days). This trial was registered at www.clinicaltrials.gov as #NCT01349049.
Introduction
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most frequently found mutations in acute
myeloid leukemia (AML).1,2 Constitutively activating internal tandem duplication (ITD) mutations are the
most commonly identified mutations in FLT3. ITD mutations occur in;20% to 25% of AMLs and confer
poor prognosis.3,4 Another 5% to 10% of AMLs are associated with point mutations in the FLT3 tyrosine
kinase domain (KD), particularly at the activation loop residue D835.5,6 In recent years, a variety of
tyrosine kinase inhibitors (TKIs) of FLT3 have entered clinical development in AML, with variable
success. Midostaurin, a multitargeted inhibitor, demonstrated little activity as monotherapy7 but
significantly prolonged survival compared with placebo when added to induction chemotherapy in newly
Submitted 6 January 2020; accepted 25 March 2020; published online 24 April 2020.
DOI 10.1182/bloodadvances.2020001449.
All data and the full clinical trial protocol will be made available upon request by
contacting corresponding author Catherine C. Smith (catherine.smith@ucsf.edu).
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
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diagnosed patients with FLT3mutations.8 This clinical activity led to
US Food and Drug Administration (FDA) approval of midostaurin in
newly diagnosed FLT3-mutant AML. More potent and selective
next-generation FLT3 inhibitors such as quizartinib9,10 and gilter-
itinib11 have entered clinical development in AML and, in contrast to
midostaurin, have demonstrated high response rates as mono-
therapy in relapsed/refractory (R/R) patients with FLT3 muta-
tions. Both quizartinib12 and gilteritinib13 have also demonstrated
a survival benefit when compared with salvage chemotherapy in
R/R FLT3-mutant AML patients, leading to the recent FDA approval
of gilteritinib for this indication. Despite this, survival in this R/R
group of patients remains limited by the development of therapeutic
resistance.
Despite leading to composite complete remission (CRc) rates of
40% to 50%9,10 in R/R FLT3-ITD1 AML, quizartinib is highly
vulnerable to acquired resistance-conferring mutations in the FLT3
KD, which occur at the activation loop residue D835 and the
kinase gatekeeper residue F691.14 Mutations at these residues
have also been implicated in resistance to other FLT3-targeted
TKIs, including sorafenib15,16 and sunitinib.15 Type 1 FLT3
inhibitors, such crenolanib and gilteritinib, which bind to the FLT3
active kinase conformation, have been developed to combat
quizartinib resistance–conferring D835 mutations and have dem-
onstrated clinical activity against cases with D835 mutations, with
and without cooccurring FLT3-ITD mutations.11,17 However, both
crenolanib18,19 and gilteritinib20,21 are vulnerable to resistance
induced by F691 mutations. Patients treated with either crenolanib
or gilteritinib therapy have developed F691L mutations as a cause
of clinical resistance.19,21 At this time, limited treatment options
exist for patients with FLT3 TKI resistance resulting from F691
mutations. The ABL/FLT3 inhibitor ponatinib, which was rationally
designed to inhibit the BCR-ABL gatekeeper mutation T315I, has
demonstrated equivalent in vitro activity against the analogous FLT3
F691I mutation but has shown decreased efficacy against the more
clinically relevant F691L substitution.22 Ponatinib did induce bone
marrow responses in 3 of 12 R/R AML patients in a phase 1 clinical
trial23; however, no responding patients were known to express
FLT3 F691 mutations, and the activity of ponatinib in FLT3-
ITD–mutant AML, with or without F691 mutations, has not been
confirmed in larger clinical trial experience. Cabozantinib, a multi-
kinase inhibitor of FLT3, MET, AXL, KIT, and VEGFR, has shown
in vitro activity against FLT3 F691 mutations, but no bone marrow
responses were observed in a dose-escalation clinical trial in
AML.24 The common development of resistance-causing FLT3 KD
mutations in patients who respond to and relapse on FLT3-targeted
therapy underscores the central importance of FLT3 signaling in
these patients. However, even with the development of FLT3 TKIs
with expanded activity against FLT3 KD mutations, there continues
to be no established therapeutic option for patients in whom FLT3
TKI therapy fails because of F691 mutations.
Pexidartinib (formerly PLX3397) is a selective small-molecule
kinase inhibitor of CSF1R, KIT, and FLT3-ITD, with a novel chemical
structure comprising a pyridine (rather than phenyl) middle ring and
a methyl amine (rather than amide or urea) linker, designed to retain
binding to FLT3 with a F691L mutation. Based on its activity against
CSF1R, pexidartinib was recently approved for the treatment of
advanced tenosynovial giant cell tumor, a neoplasm the growth of
which is related to CSF1R. In preclinical studies, pexidartinib has
demonstrated equipotent activity in cells expressing FLT3-ITD/
F691L mutations compared with cells expressing FLT3-ITD alone,
although it remains vulnerable to FLT3 D835 mutations.25 To
assess the safety and efficacy of pexidartinib in R/R FLT3-
ITD–mutant AML, we conducted a phase 1/2 open-label, sequential
dose-escalation study followed by a cohort expansion at the
recommend phase 2 dose (RP2D) of continuous oral administration
of pexidartinib in 28-day cycles.
Patients and methods
Study design
This open-label phase 1/2 study evaluated the safety and tolerability
of continuous oral administration of pexidartinib in R/R AML patients
with FLT3-ITD mutations. The study consisted of a dose-escalation
phase to determine the maximum tolerated dose (MTD)/RP2D,
followed by a dose-expansion cohort treated at the RP2D. Patients
received pexidartinib orally twice daily in a capsule formulation (100
or 200 mg per capsule) on days 1 through 28 of each 28-day cycle,
beginning on cycle 1 day 1 (C1D1). Dose escalation followed
a standard 3 1 3 dose-escalation design, based on dose-limiting
toxicities (DLTs) during the first 15 days of pexidartinib therapy.
A DLT was defined as any adverse event (AE) with a Common
Terminology Criteria for Adverse Events (version 4) grade $3
severity that was not due to AML and occurred within the first
15 days of treatment initiation. No hematologic DLTs were defined
for this protocol. The following doses were administered in part 1 of
the study: 800, 1000, 1200, 1400, 2000, 3000, 4000, and
5000 mg per day in split doses. The RP2D was the MTD or the dose
level that achieved maximal plasma concentration if an MTD was not
reached. Each patient was offered continued dosing with pex-
idartinib as long as it was well tolerated and the patient was clinically
benefitting from treatment. Patients in part 1 and part 2 who were
tolerating the study drug but who had evidence of tumor
progression at C1D15 remained on study treatment until the
C2D1 assessment. Patients continued study drug until unaccept-
able toxicity or DLT, disease progression or relapse, patient death,
or patient decision. Patients who discontinued for reasons other
than withdrawal of consent were followed up every 3 months (for up
to 2 years) for disease, treatment, and survival status. For part 1,
hydroxyurea was permitted at any time, at a dose of #5 g per day.
For part 2, hydroxyurea was permitted only during the first 2 weeks
of treatment, at a dose of #5 g per day. For patients in part 1, dose
reductions and interruptions were permitted during the first 15 days
of cycle 1 only if a patient experienced a DLT. If a patient
experienced a DLT, treatment continuation at a lower dose was
permitted at the discretion of the investigator and in consultation
with the medical monitor. After C1D15, dose reductions or
interruptions for AEs could take place at any time. Reduction/
interruption of dosing for AEs could take place at any time in part 2.
The study was conducted in compliance with the protocol, Good
Clinical Practice, and the applicable regulatory requirements
(including International Conference on Harmonisation guidelines)
and in accordance with ethical principles founded in the Declaration
of Helsinki. All participants gave written informed consent. All
authors had access to the data on request.
Study objectives
The primary objective in part 1 was to determine the safety and
tolerability of escalating doses of pexidartinib and establish an
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RP2D in patients with relapsed or refractory FLT3-ITD1 AML. The
primary objective in part 2 was to determine the overall response
rate (ORR) of pexidartinib at the RP2D.
Study population
Eligibility required a diagnosis of primary AML or secondary AML
as per the World Health Organization criteria. Marrow involvement
by leukemia was required at screening for enrollment in part 2.
Patients were required either to be refractory to initial induction
attempt (up to 2 cycles of standard cytotoxic chemotherapy) or to
have relapsed after prior CR. The presence of an FLT3-ITD
mutation was required from blood or marrow testing at screening
using the FLT3-ITD/wild type allelic ratio cutoff defined by local
laboratory testing. Patients with history of FLT3-ITD1 leukemia
who did not have demonstrable FLT3-ITD at screening could be
enrolled after discussion with the study medical monitor. Prior
FLT3 inhibitor therapy was allowed, but those with a history
of FLT3-TKD mutations at D835 (or for part 2, their presence
at screening) were excluded from participation. Patients were
required to have resolution of toxicities from prior therapy to grade
#1, adequate hepatic and renal function at baseline, and
Eastern Cooperative Oncology Group performance status of 0
to 2. Patients with prior hematopoietic stem cell transplantation
(HSCT) were eligible as long as they were .60 days from
transplantation and did not have clinically significant graft-versus-
host disease at screening (part 1 only). Patients with diagnosis of
acute promyelocytic leukemia, chronic myeloid leukemia, central
nervous system leukemia, or active malignancy; with prolonged
corrected QT interval by Fredericia (.450 ms for men; .470 ms
for women); or who had received treatment with any investiga-
tional drug within 28 days were excluded. Patients with refractory
nausea/vomiting, gastrointestinal malabsorption, or other serious
concurrent uncontrolled illness were also excluded.
Response assessment
Response to treatment was evaluated using a modified ver-
sion of the International Working Group response criteria.26,27
Responses were defined per standard criteria except that
participants achieving a CR with incomplete hematologic recovery
(CRi) or a partial response (PR) were not required to be transfu-
sion independent26 (data supplement provides detailed response
criteria). The primary efficacy end point was the rate of CRc, which
included CR, CRi, and CR with incomplete platelet recovery (CRp)
based upon modified International Working Group response
criteria, plus the percentage of patients who were successfully
bridged to transplantation, defined as any patient who discontinued
pexidartinib treatment specifically for the purpose of undergoing
HSCT and who subsequently received the planned transplant.
Secondary end points included PR, duration of remission, overall
survival (OS), and progression-free survival (PFS). PFS was defined
as the number of days from the start of therapy to the date of
documented disease progression/relapse or death, whichever
occurred first.
Results
Patient characteristics and disposition
A total of 90 patients with R/R FLT3-ITD1 AML were enrolled in the
study (part 1, n5 34; part 2, n5 56) and received at least 1 dose of
pexidartinib. Patients were enrolled at 8 sites in the United States.
The first patient was enrolled on 21 November 2011, and the data
cutoff date was 20 January 2015. Demographics and baseline
disease characteristics are shown in Table 1. Median age of
patients was 62.5 years (range, 24-82 years) in part 1 and
59.5 years (range, 22-83 years) in part 2. A lower percentage of
male patients (38%) were enrolled in part 1, but a higher
percentage of men were enrolled in part 2 (59%). Of all 90
patients, 70 had de novo AML and 12 had AML secondary to an
antecedent hematologic disorder. In 8 patients, it was not known if
Table 1. Summary of demographics and AML history
Characteristic Part 1 (n 5 34) Part 2 (n 5 56)
Age, y
Mean 60.6 55.9
Standard deviation 14.6 14.6
Minimum-maximum 24-82 22-83
Sex
Male 13 (38) 33 (59)
Female 21 (62) 23 (41)
Race
American Indian or Alaskan Native 1 (3) 0
Asian 1 (3) 3 (5)
Black or African American 7 (21) 7 (13)
White 21 (62) 35 (63)
Other 4 (12) 11 (20)
Ethnicity
Hispanic or Latino 1 (3) 5 (9)
Not Hispanic or Latino 33 (97) 51 (91)
ECOG performance status
Fully active (0) 6 (18) 9 (16)
Restricted (1) 17 (50) 33 (59)
Ambulatory (2) 11 (32) 14 (25)
AML category at diagnosis
De novo 26 (76) 44 (79)
Secondary to MDS 4 (12) 2 (4)
Secondary to chemotherapy for another cancer 2 (6) 4 (7)
Unknown 2 (6) 6 (11)
FLT3-ITD1 at diagnosis
Yes 30 (88) 45 (80)
No 2 (6) 4 (7)
Unknown 2 (6) 7 (13)
Prior FLT3 inhibitor therapy 14 (41) 12 (21)
Prior allogeneic transplantation
Yes 7 (21) 21 (38)
No 27 (79) 34 (61)
Unknown 0 1 (2)
No. of prior AML therapies
Median 4 4
Range 2-12 1-10
Values are n (%) unless otherwise noted.
ECOG, Eastern Cooperative Oncology Group; MDS, myelodysplastic syndrome.
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AML was de novo or secondary. At screening, 89 (99%) of the
enrolled patients were FLT3-ITD mutation positive, and 1 patient
with a history of FLT3-ITD was mutation negative. A total of 28
patients (31%) had undergone prior allogeneic transplantation.
Median number of prior AML therapies was 4 (range, 1-12;
supplemental Figure 1); 27 patients (30%) had received prior FLT3
inhibitor therapy, most commonly sorafenib (n 5 23; 26%) and/or
quizartinib (n 5 5; 6%), and 1 patient had participated in
a randomized clinical trial of PKC412; a majority of patients had
received 1 prior FLT3 inhibitor, but 2 (7.4%) of 27 patients had
received both quizartinib and sorafenib. Patient disposition is shown
in Figure 1.
Safety
In part 1 dose escalation, pexidartinib was investigated at 8 dose
levels (800-5000 mg). One patient in the 1000-mg dose group
experienced grade 3 bilirubin elevation, which was a DLT but
considered unrelated to study treatment. Although this AE was
considered unrelated to pexidartinib, additional patients were
enrolled in the 1000-mg dose group (n 5 7). Patients in the next
2 dose cohorts, 1200 (n5 3) and 1400 mg (n5 3), completed the
15-day observation period without the occurrence of a DLT, and the
dose was escalated to 2000 mg. One patient in the 2000-mg dose
group experienced a DLT of atrial fibrillation, considered unrelated
to study medication. The DLT was not discovered until later medical
review of the data, and the 2000-mg dose cohort was not
expanded. The dose was escalated 3 additional times, to 3000,
4000, and 5000 mg. No protocol-defined DLTs were reported.
Evaluation of available pharmacokinetic (PK) data indicated that
pexidartinib plasma exposure levels peaked at ;3000 mg per day
and that higher dose levels did not provide higher plasma levels.
800 mg
N=3
1000 mg
N=7
1200 mg
N=3
1400 mg
N=3
Part 1
N=34
Treated
N=90
Enrolled
N=90
Part 2
3000 mg
N=56
Screen
Failures
N=36
Screened
N=126
2000 mg
N=3
3000 mg
N=6
4000 mg
N=5
5000 mg
N=4
Disease
Progression
3
Disease
Progression
5
Adverse Event
1
PI Decision
1
Disease
Progression
3
Disease
Progression
2
Non-
compliance
1
Disease
Progression
2
Stem Cell
Transplant
1
Adverse Event
3
Disease
Progression
2
Other
1
Disease
Progression
3
Adverse Event
1
Stem Cell
Transplant
1
Disease
Progression
2
Death
1
Stem Cell
Transplant
1
Disease Progression 33
Subject Decision 6
Death 5
Adverse Event 4
PI Decision 2
Protocol Violation 1
Other 4
Figure 1. Patient disposition. PI, principal investigator.
Table 2. Summary of all TEAEs that occurred in ‡20% of patients
Preferred term Grade 1-2 Grade ‡3 All grades
Diarrhea 44 (49) 1 (1) 45 (50)
Fatigue 33 (37) 9 (10) 42 (47)
Nausea 40 (44) 1 (1) 41 (46)
Febrile neutropenia 0 (0) 38 (42) 38 (42)
Decreased appetite 31 (34) 2 (2) 33 (37)
Vomiting 32 (36) 1 (1) 33 (37)
Cough 26 (29) 0 (0) 26 (29)
Anemia 9 (10) 15 (17) 24 (27)
Hypokalemia 16 (18) 6 (7) 22 (24)
Aspartate aminotransferase increased 14 (16) 5 (6) 19 (21)
Dyspnea 15 (17) 3 (3) 18 (20)
Values are n (%). TEAE defined as AE with start date on or after C1D1.
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After extensive discussion, all investigators and the sponsor agreed
that pexidartinib at 3000 mg per day was the appropriate R2PD.
This dose was used in all 56 patients enrolled in part 2 dose
expansion.
A summary of AEs is shown in supplemental Table 1. All patients
(n 5 90; 100%) who received study medication during this study
experienced at least 1 AE. The most frequent treatment-emergent
AEs (TEAEs) of pexidartinib are summarized in Table 2. A total of 81
patients (90%) experienced an AE that was Common Terminology
Criteria for Adverse Events grade $3 (supplemental Table 2). A
summary of all TEAEs occurring in the first 30 days of treatment is
shown in supplemental Table 3. The most frequently reported TEAE
was diarrhea (50% of all patients), followed by fatigue (47%),
nausea (46%), and febrile neutropenia (42%). The most frequently
reported TEAE that led to changes in study medication administra-
tion was febrile neutropenia (12%), followed by sepsis (6%) and
aspartate aminotransferase increase (6%). Of note, 4 patients, all
treated at 3000 mg, experienced a change in hair color, an
Table 3. Mean plasma PK parameters of pexidartinib in AML patients after oral administration for 1 day (C1D1) and 15 days (C1D15)
Daily dose, mg (cohort)
C1D1 C1D15
Cmax, ng/mL AUC0-4, ng 3 h/mL AUC0-6, ng 3 h/mL Cmax, ng/mL AUC0-4, ng 3 h/mL AUC0-6, ng 3 h/mL
800 (part 1, 1)
n 3 3 3 3 3 3
G-mean 1148 3300 5184 4134 12340 20147
CV, % 133 121 111 47.4 78.9 64.2
1000 (part 1, 2)
n 6 6 6 5 5 5
G-mean 2163 4566 8008 7294 22949 34013
CV, % 44.6 63.8 48.7 25.7 31.6 37.2
1200 (part 1, 3)
n 3 3 3 3 3 3
G-mean 2016 5392 8171 4291 14870 21595
CV, % 92.5 92.2 93.7 110 103 112
1400 (part 1, 4)
n 3 3 3 3 3 2
G-mean 2534 5510 8868 7593 25121 30857
CV, % 96.3 139 101 40 37.4 36.3
2000 (part 1, 5)
n 3 3 3 3 3 3
G-mean 3493 7159 12133 10633 37214 54464
CV, % 117 153 97.5 61.2 53.6 48
3000 (part 1, 6)
n 6 6 6 5 5 4
G-mean 6132 16550 24986 12124 38834 58329
CV, % 51.6 58.6 67.5 45.1 42 47.6
4000 (part 1, 7)
n 5 5 5 4 4 4
G-mean 3669 6530 12766 10406 34446 51415
CV, % 57.6 166 101 45.8 54.3 47.3
5000 (part 1, 8)
n 4 4 4 4 4 4
G-mean 4714 11701 18881 11987 39477 56460
CV, % 35.8 27.6 35.6 35.6 43.2 44.3
3000 (part 2)
n 56 56 55 48 48 47
G-mean 4816 10910 18495 12794 43067 62451
CV, % 66 62.6 60.9 30.8 28 28.8
AUC0-4, area under the curve from d 0 to d 4; AUC0-6, AUC from d 0 to d 6; Cmax, maximum serum concentration; CV, coefficient of variation; G-mean, geometric mean.
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associated AE of potent inhibition of c-KIT,28 a known target of
pexidartinib. The most frequent grade $3 TEAE was febrile
neutropenia (42%). Twelve patients (13%) experienced fatal AEs
during this study: 3 during part 1 and 9 during part 2. Causes of
death were sepsis (n 5 5), pneumonia (n 5 2), pneumonia
aspiration (n5 1), respiratory failure (n5 1), cardiac arrest (n5 1),
cytokine release syndrome (differentiation syndrome; n 5 1), and
cerebral hemorrhage (n 5 1). In 11 of 12 patients, study drug had
been discontinued before death. All AEs that resulted in death were
considered unrelated to study medication, with the exception of
1 patient in part 2 who experienced grade 5 cytokine release
syndrome as a result of treatment-induced differentiation syndrome,
a known potential complication of FLT3 inhibitor response.29
Patients were withdrawn from study because of disease progression
(n 5 55), AE (n 5 9), death (n 5 6), patient decision (n 5 6), other
(n5 5), investigator decision (n5 3), elective HSCT (n5 3), protocol
violation (n 5 1), and noncompliance (n 5 1). There were no
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Figure 3. Best clinical response, treatment duration, and survival. (A) Number and proportion of best response (modified criteria) per patient by cohort. Includes all
patients with a best response of at least PR. Bars are overlaid with the geometric mean of steady-state AUC0-6 (ng 3 h/mL) for each cohort. The ORR for the study was 19
(21%) of 90 and CRc rate is 10 (11%) of 90. (B) Best percentage change in blasts is shown for individual patients, and bars are blue gradient–filled with steady-state AUC0-6.
Gray-filled bars indicate that AUC0-6 was not determined. Patients who were successfully bridged to transplantation are shown with solid triangles. Best response by modified
criteria is indicated at the top of each bar. (C) Treatment duration is represented by a gray line drawn from C1D1 to the day of last known dose. If last dose day is unknown,
gray line extends to the day of study discontinuation or database lock. Response assessments by modified criteria are shown with color-coded boxes. Empty boxes indicate
that a patient was not assessable (NA). The day of disease progression or death (end PFS), whichever came first, is marked with a red "3." In part 1 of the study, 2 patients
were successfully bridged to transplantation (07_002 [2000 mg] and 07_004 [5000 mg]), discontinued the study drug to undergo HSCT, and did not resume pexidartinib
treatment. In part 2, 4 patients were successfully bridged to transplantation. Of these, 2 patients (03_009 and 06_013) resumed maintenance treatment with pexidartinib, as
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apparent trends in changes in chemistry or hematology parameters
throughout the study. No clinically significant electrocardiogram
abnormalities were observed at the end of treatment assessment.
Echocardiogram/multigated acquisition scan evaluation of ejection
fraction (EF) was not originally included in the study protocol but
was added because of grade 3 decreased EF noted in 1 patient
with unknown baseline EF treated at 5000 mg. Echocardiogram/
multigated acquisition assessment was performed for 3 patients in
part 1 and for 19 patients in part 2. Two of these patients in part 2
had .10% decrease in EF (grade 2, n 5 1; grade 3, n 5 1).
Assessment of lung diffusion capacity and lung computed
tomography scan were also added later in the study because of 2
early reports of pneumonitis (grades 1 and 2) and 1 report of grade
3 dyspnea with bilateral opacities on chest radiograph thought to be
possibly drug related. Results of the diffusion capacity assessment
demonstrated impaired lung function in some patients but did not
change with drug treatment. Clinically significant abnormal com-
puted tomography scans were noted in 9 patients; in 6 of these 9
patients, abnormalities were considered to have resulted from
infection; in 3 of 9, no potential etiology was given for diffuse ground
glass opacities (n 5 1), small pulmonary nodules (n5 1), or pleural
effusion (n 5 1).
PKs and pharmacodynamics
The PK population of study PLX108-05 consisted of 90 patients in
part 1 and part 2. The C1D1 and C1D15 PK parameters are
summarized in Table 3. The C1D15 exposures, as assessed by
maximum serum concentration, AUC0-4, and AUC0-6, were more
than twofold higher than C1D1 exposures at all 8 dose levels
(Table 3), indicating significant accumulation at steady state. Nearly
dose-proportional increase in steady-state (C1D15) exposure was
observed from the 800- to 3000-mg daily dose (AUC0-6, 20 147-
58 329 ng 3 h/mL) in part 1 patients (Table 3). When the
relationship between dose and steady-state (C1D15) exposure was
investigated using the power model, log (AUC0-6) 5 a 1 (b 3 log
[dose]), the intercept a and slope bwere determined to be 1.96 and
0.8146, respectively, with an R2 of 0.7665 (Figure 2A). Further
increase in exposure was not observed at doses .3000 mg.
At steady state, the geometric mean AUC0-6 values at 3000-,
4000-, and 5000-mg doses (n 5 4 for each dose) were 58 329,
51 415, and 56 460 ng 3 h/mL, respectively (Table 3), with
significantly overlapping 90% confidence intervals (CIs; 34 256-
99 317, 30 300-87 245, and 34 318-92 888 ng 3 h/mL, re-
spectively). The relatively small sample size used in this study,
however, did not allow a definitive conclusion on the plateauing
of PKs at 3000 mg. It is possible that AUCs might be higher with
4000- and 5000-mg doses. However, PK improvement, if any,
from a dose .3000 mg is likely to be offset by the challenges of
greater pill burden. The 3000-mg dose was therefore chosen as
the RP2D and administered in part 2 of the study. The geometric
mean steady-state exposure (AUC0-6, 62 451 ng 3 h/mL; 90%
CI, 58 280-66 919 ng 3 h/mL) in part 2 patients (n 5 47) was
similar to the mean exposure in part 1 patients at the RP2D (AUC0-
6, 58 329 ng 3 h/mL; Table 3). Note that this study was not
powered to determine the effects of dose-independent factors
(eg, food, hepatic or renal impairment, drug-drug interactions) on
the exposure of pexidartinib.
Efficacy
Based on modified response criteria, the ORR to pexidartinib
(CR, CRi, CRp, and PR) for all treated patients was 21% (n5 19
of 90). The overall CRc (CR, CRi, and CRp) rate for the study
was 11% (n 5 10 of 90). Of patients treated at $2000 mg, 23%
(n5 17 of 74) responded (CRc, n5 9 [12.2%] of 74; Figure 3A).
One patient who received 2000 mg in part 1 and 1 patient in part
2 achieved CR. Two patients in part 1 (1400- and 2000-mg dose
groups) achieved CRi. Six patients in part 2 achieved CRi or
CRp. Four patients in part 1 (1000, 2000, 4000, and 5000 mg)
achieved PR, and 5 patients in part 2 achieved PR. Six patients
underwent HSCT (3 of 6 after response; PR, n 5 1; CRi, n 5 1;
CRp, n 5 1). After a protocol amendment to allow maintenance
after HSCT, 3 patients bridged to transplantation resumed
maintenance therapy with pexidartinib. Of the 3 patients who
received pexidartinib maintenance, 2 discontinued maintenance
(1 of these patients relapsed 6 months after transplantation, and
1 relapsed 2 years after transplantation), and 1 patient (05_017)
was still alive on treatment without relapse at the time of database
lock. Of the remaining 3 patients, 2 relapsed ,100 days
posttransplantation, and 1 was lost to follow-up. A majority of
evaluable patients had some reduction in their marrow blast
counts (n 5 31 [74%] of 42; Figure 3B). Looking at the best
percentage change in blasts by steady-state exposure showed
a weak but significant exposure-response relationship (Pearson’s
1-sided correlation test r523.06;P5 .037; supplemental Figure 2).
However, no significant difference in steady-state exposure was
noted between responders (achieving CRc) and nonresponders
(supplemental Figure 2).
For patients in part 1, median duration of response was 74 days,
median PFS was 57 days, and median OS was 91 days. For
patients in part 2, median duration of response was 76 days, median
PFS was 48 days, and median OS was 112 days (Figure 3C).
Median time to best response was 30 days in both part 1 and part 2.
In responders ($PR), median PFS and OS were extended by 98
and 171 days, respectively, compared with nonresponders (Figures
3D; supplemental Figure 3). Median OS of complete responders
(CRi, CRp, or CR) was 265 days (90% CI, 170-422 days;
supplemental Figure 4). Median duration of CRc (from 9 responders
evaluable for duration of response) was 212 days (90% CI, 37-370
days). Median PFS and OS for patients dosed at $3000 mg
(RP2D, 3000 mg) were not significantly different than for patients
who received lower doses (supplemental Figure 5). We also found
that FLT3-ITD length did not affect PFS (Cox proportional hazards
hazard ratio, 0.998; 90% CI, 0.9925-1.004; P 5 .6; supplemental
Data; supplemental Figure 6). In this heavily pretreated population,
the observed response rate was lower in FLT3 TKI–pretreated
patients. Four (14.8%) of 27 patients with FLT3 TKI pretreatment
were responders (CR, n5 1; PR, n5 3) compared with 15 (23.8%)
of 63 FLT3 TKI–naı¨ve patients (supplemental Figure 7). In all 4
responders, the prior FLT3 TKI treatment was sorafenib. OS did not
Figure 3. (continued) provided for by protocol amendment 7, but later discontinued treatment because of an AE or voluntary withdrawal from the study. One patient
(05_017) resumed treatment with pexidartinib and was still on treatment at database lock, and 1 patient (06_022) did not resume study treatment. (D) OS stratified by
response ($PR). PD, progressive disease; SD, stable disease.
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differ between patients with prior FLT3 inhibitor exposure amd
patients who were FLT3 inhibitor naı¨ve (supplemental Figure 7).
To assess the potential clinical activity of pexidartinib in patients
expressing FLT3 F691L mutations, we sequenced the FLT3 KD
from 42 patients with available blood or bone marrow samples
collected before pexidartinib treatment. Four patients had detect-
able F691L mutations at the time of study drug initiation
(supplemental Table 4). All 4 patients were treated below the
RP2D of 3000 mg per day (1000 mg, n5 2; 1200 mg, n5 1; 2000
mg, n5 1). Three of the 4 patients had no response to pexidartinib.
One patient (5.02), treated at 2000 mg, had an F691L mutation
detectable in 2.58% of native FLT3 (non–ITD containing) alleles
and achieved a CRi. Of note, at the time of pexidartinib relapse, no
F691L mutation was detected, and this patient instead had
acquired a new D835Y mutation (data not shown). Additionally, in
a previous analysis of 9 patients who achieved response on
pexidartinib, no patients had developed new F691L mutations at the
time of disease relapse.25
Discussion
Results of this phase 1/2 study demonstrate that pexidartinib was
well tolerated and had antileukemic activity in a population of heavily
pretreated R/R AML patients with FLT3-ITD mutations. No MTD of
pexidartinib was reached in this study. The overall safety profile of
pexidartinib in this study was similar to that of other FLT3-targeted
inhibitors in clinical development.10,11 As expected in patients with
acute leukemia, treatment-emergent infectious complications, such
as febrile neutropenia, sepsis, and pneumonia, were common and
resulted in death in 8% of patients.
Pexidartinib demonstrated clear antileukemic activity in FLT3-ITD1
AML. The ORR to pexidartinib for all treated patients was 21%, with
a CRc rate of 11%. Six patients in the study were successfully
bridged to allogeneic stem cell transplantation. Overall, the single-
agent response rate for pexidartinib was lower than the ;40% to
50% CRc rates observed with quizartinib9,10 or gilteritinib11 in
similar patient populations. The prior use of other type 2 FLT3
inhibitors, such as sorafenib and quizartinib, in a large proportion
of enrolled patients may have contributed to primary resistance
(27 [30%] of 90 the patients comprising the overall study population
had receiving prior FLT3 TKI treatment). However, the response
rate in patients without prior TKI treatment was not substantially
different than that of the study population as a whole (15 [23.8%] of
63 patients without prior TKI treatment responded). The lower
response rate to pexidartinib may also be attributable to the overall
lower potency of pexidartinib compared with either quizartinib or
gilteritinib (;1000 or 100 times less potent, respectively, in cell-
based assays).25,30,31 In keeping with this idea, the dose required
for .95% median inhibition of FLT3 phosphorylation assessed by
plasma inhibitory activity was$3000 mg. Our PK data suggest that
3000 mg achieved the maximal possible pexidartinib drug level in
patients and that higher doses did not result in increased exposure.
Because prolonged and potent inhibition of FLT3 kinase activity is
an important prerequisite to achieve clinical response,32 it is
possible that inability to achieve sufficient exposure to pexidartinib
limited clinical response in a significant proportion of patients, as
suggested by the exposure-response correlation shown in supple-
mental Figure 2. Notably, 4% of patients experienced treatment-
emergent changes in hair color, indicative of in vivo kinase inhibition
of c-KIT,28 a kinase target against which pexidartinib has activity
equivalent to its activity against FLT3-ITD.
Resistance-associated FLT3 KD mutations have been an important
cause of clinical resistance to all FLT3 TKIs to date, particularly type
2 inhibitors. Pexidartinib is no exception to this paradigm, and we
previously reported the acquisition of polyclonal FLT3-ITD KD
mutations, including D835 mutations, at the time of disease
progression in 6 of 9 pexidartinib responders.25 Conversely, the
development of acquired resistance to pexidartinib as a result of
FLT3-ITD KD mutations confirms that the clinical activity of
pexidartinib is mediated by inhibition of FLT3 and not by another
of its targets, such as KIT or CSF-1R. Although pexidartinib is
vulnerable to D835 mutations commonly found in association
with clinical resistance to quizartinib and sorafenib, it does have
potent activity against the FLT3 F691L gatekeeper mutation also
commonly associated with acquired FLT3 TKI resistance. AML
patients treated with quizartinib,14 sorafenib,15 sunitinib,15 gilter-
itinib,21 and crenolanib19 have all developed clinical resistance as
a result of FLT3 F691 mutations. FLT3 F691L mutations are the
most common KD mutations associated with clinical resistance to
type 1 FLT3 TKIs crenolanib and gilteritinib. Given the recent FDA
approval of gilteritinib in R/R FLT3-mutant AML, F691L mutations
may become a more commonly encountered cause of relapse in
patients. Because all currently FDA-approved FLT3 inhibitors
except midostaurin have demonstrated in vitro18 and/or clinical15,21
vulnerability to FLT3 F691L mutations, and midostaurin has no
single-agent efficacy in this disease,7 pexidartinib may have
a potential role in the treatment of patients resistant to gilteritinib
(or other FLT3 TKIs) who relapse with F691L mutations. Un-
fortunately, in this study, only a small minority of patients treated
below the R2PD were known to have F691L mutations before
pexidartinib initiation, although 1 patient treated at 2000 mg did
respond. Additionally, unlike with other FLT3 TKIs,14,15,19,21 the
F691L mutation was not associated with pexidartinib relapse in
a limited analysis of 9 responding patients.25 However, future
studies will be required to determine the true clinical activity of
pexidartinib in patients with FLT3 F691L mutations. Recently,
translational studies in patients treated with crenolanib19 and
gilteritinib21 have also established a variety off-target mechanisms,
particularly Ras pathway mutations, as important mediators of FLT3
TKI resistance. Despite activity against FLT3 F691L mutations, it is
likely that pexidartinib will also be vulnerable to these non–FLT3-
dependent mechanisms of resistance. It is also possible that the
unique kinase profile of pexidartinib may contribute to clinical activity
in AML in patients without FLT3 mutations. For example, a role for
the targeting of CSF1R signaling–dependent supporting cells in
AML has also been recently described33 and may be another
rationale for the use of pexidartinib in AML patients. Overall, the
safety, tolerability, and clinical activity of pexidartinib in the heavily
pretreated R/R AML population described in this study are
supportive of the further development of pexidartinib in AML.
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